
Elafibranor (Iqirvo®) Advances to Phase 3 Clinical Trial for PSC
Significant and encouraging clinical trial news in the field of primary sclerosing cholangitis (PSC) drug development. The trial sponsor, Ipsen and developer, GENFIT, announced on Feb. 12, 2026, that elafibranor has progressed to a Phase 3 clinical trial for PSC, known as the ELASCOPE study. Advancing to a Phase 3 trial represents an important milestone … Read more








